|
[Greeting] [Title] [Name],
|
|
I’m sorry I missed you, but we should still connect to discuss the key issues your patients with Parkinson’s disease (PD) are facing.
|
|
|
|
For almost 50 years, carbidopa/levodopa (CD/LD) has been the gold standard foundational treatment for PD.1-3
|
|
|
|
Despite nearly 1 million people affected, current treatment options don’t fully address the varying and evolving needs of patients with PD.3-5
|
|
That’s why Avion has taken a thoughtful approach to supporting the unique needs of patients and is committed to helping the PD community face a brighter future.
|
| |
|
Please let me know what time is best for you and we can set up another [call/meeting]. I look forward to learning more about your practice and experiences with your PD patients.
|
|
Feel free to reach me at:
|
|
[rep email] | [rep phone number]
|
|
Sincerely,
|
|
[rep name]
|
|
[rep title]
|
|
[rep photo]
|
|
Understand the burden
|
|
|
References: 1. Olanow CW, Calabresi P, Obeso JA. Continuous dopaminergic stimulation as a treatment for Parkinson’s disease: current status and future opportunities. Mov Disord. 2020;35(10):1731-1744. doi:10.1002/mds.28215.
2. Tolosa E, Martí MJ, Valldeoriola F, Molinuevo JL. History of levodopa and dopamine agonists in Parkinson’s disease treatment. Neurology. 1998;50(6 suppl 6):S2-S10. doi:10.1212/wnl.50.6_suppl_6.s2. 3. Tanner CM. Exploring the clinical burden of OFF periods in Parkinson disease. Am J Manag Care. 2020;26(12 suppl):S255-S264. doi:10.37765/ajmc.2020.88517. 4. Yang W, Hamilton JL, Kopil C, et al. Current and projected future economic burden of Parkinson’s disease in the U.S. NPJ Parkinsons Dis. 2020;6:15. doi:10.1038/s41531-020-0117-1. 5. Stoker TB, Greenland JC, eds. Parkinson’s Disease: Pathogenesis and Clinical Aspects. Codon Publications; 2018.
|
|
|
